Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALEC
stocks logo

ALEC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.09M
-96.16%
-0.387
+1833.35%
0.00
-100%
-0.415
+1.22%
0.00
-100%
-0.395
+31.67%
Estimates Revision
The market is revising Downward the revenue expectations for Alector, Inc. (ALEC) for FY2025, with the revenue forecasts being adjusted by -4.87% over the past three months. During the same period, the stock price has changed by -59.80%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.87%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.58%
In Past 3 Month
Stock Price
Go Down
down Image
-59.80%
In Past 3 Month
Wall Street analysts forecast ALEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALEC is 2.06 USD with a low forecast of 0.75 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ALEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALEC is 2.06 USD with a low forecast of 0.75 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
5 Hold
2 Sell
Hold
Current: 1.210
sliders
Low
0.75
Averages
2.06
High
5.00
Current: 1.210
sliders
Low
0.75
Averages
2.06
High
5.00
Morgan Stanley
NULL -> Underweight
downgrade
2025-11-17
Reason
Morgan Stanley
Price Target
2025-11-17
downgrade
NULL -> Underweight
Reason
Morgan Stanley lowered the firm's price target on Alector to 75c from $1.50 and keeps an Underweight rating on the shares. The firm, which is updating its model to account for the Phase 3 INFRONT-3 trial evaluating latozinemab failing to meet its co-primary endpoint, now includes revenues for AL101 in Alzheimer's disease but in a "heavily discounted" fashion, the analyst tells investors.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$10 -> $5
2025-10-22
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $5
2025-10-22
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Alector to $5 from $10 and keeps a Buy rating on the shares. The firm removed AL001 from the stock's valuation following the INFRONT-3 data miss. However, it believes Alector's AL137, AL050, and ADP064-ABC offer "diversified, large market optionality, creating multiple potential paths to upside."
Mizuho
Outperform
to
Neutral
downgrade
2025-10-22
Reason
Mizuho
Price Target
2025-10-22
downgrade
Outperform
to
Neutral
Reason
Mizuho downgraded Alector to Neutral from Outperform with a price target of $1.50, down from $3.50. The firm cites the negative Pahe 3 data for latozinemab for the downgrade. Alector has other pipeline candidates in development, but there is high risk associated with developing therapeutics for Alzheimer's disease, the analyst tells investors in a research note.
TD Cowen
Yaron Werber
Buy -> Hold
downgrade
2025-10-22
Reason
TD Cowen
Yaron Werber
Price Target
2025-10-22
downgrade
Buy -> Hold
Reason
TD Cowen analyst Yaron Werber downgraded Alector to Hold from Buy without a price target. The Phase 3 INFRONT-3 miss ends the company's latozinemab program and the shares have few near-term catalysts, the analyst tells investors in a research note. The firm says that while Alector's 49% headcount cut "is step in right direction," its cash burn is high with runway to 2027.
Cantor Fitzgerald
Overweight -> Neutral
downgrade
$NULL
2025-10-22
Reason
Cantor Fitzgerald
Price Target
$NULL
2025-10-22
downgrade
Overweight -> Neutral
Reason
Cantor Fitzgerald downgraded Alector to Neutral from Overweight without a price target after the company's INFRONT-3 trial of latozinemab failed to meet its primary endpoint with no directly positive benefit. Alector's other programs are too early to value, the analyst tells investors in a research note.
William Blair
Myles Minter
Outperform -> Market Perform
downgrade
2025-10-22
Reason
William Blair
Myles Minter
Price Target
2025-10-22
downgrade
Outperform -> Market Perform
Reason
William Blair analyst Myles Minter downgraded Alector to Market Perform from Outperform without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm needs to see clinical data for Alector's platform to evaluate its other programs.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alector Inc (ALEC.O) is -0.76, compared to its 5-year average forward P/E of -7.46. For a more detailed relative valuation and DCF analysis to assess Alector Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.46
Current PE
-0.76
Overvalued PE
9.51
Undervalued PE
-24.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.75
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.79
Undervalued EV/EBITDA
-9.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.56
Current PS
0.00
Overvalued PS
34.67
Undervalued PS
-5.55
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ALEC News & Events

Events Timeline

(ET)
2025-11-06
18:22:40
Alector announces Q3 earnings per share of 34 cents, falling short of the expected 41 cents.
select
2025-10-21 (ET)
2025-10-21
18:58:31
Alector halts extension phase of INFRONT-3 trial
select
2025-08-07 (ET)
2025-08-07
16:56:09
Alector sees FY25 revenue view $13M-$18M, consensus $12.56M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-27Globenewswire
Alector Shares Plunge Nearly 50% Following Phase 3 Trial Failure
  • Legal Investigation Initiated: The Schall Law Firm is investigating Alector for potential violations of securities laws, particularly regarding the issuance of false or misleading statements, indicating significant legal risks for the company.
  • Poor Clinical Trial Results: Alector's October 21, 2025 press release revealed that its drug candidate, latozinemab, failed to meet the primary clinical endpoint of slowing frontotemporal dementia progression, directly impacting investor confidence in the company's future prospects.
  • Stock Price Volatility: Following the disappointing clinical trial results, Alector's shares plummeted nearly 50% the next day, reflecting market pessimism about the company's outlook and raising concerns about its financial health among investors.
  • Investor Rights Affected: This incident has drawn attention to the rights of Alector's investors, with the Schall Law Firm urging affected shareholders to participate in the investigation, highlighting potential deficiencies in the company's transparency and information disclosure practices.
[object Object]
Preview
7.0
11-19Globenewswire
ALEC Investors Can Participate in Alector, Inc. Fraud Investigation Led by the Schall Law Firm

  • Investigation Announcement: The Schall Law Firm is investigating Alector, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors.

  • Clinical Trial Results: Alector's recent press release revealed that its drug candidate, latozinemab, failed to meet key clinical trial endpoints for treating frontotemporal dementia, leading to a significant drop in the company's stock price.

  • Investor Impact: Following the announcement of the clinical trial results, Alector's shares plummeted by nearly 50% the day after the news was released.

  • Legal Support Offer: The Schall Law Firm is offering free consultations to shareholders who may have suffered losses and encourages them to reach out for assistance regarding their rights.

[object Object]
Preview
8.0
10-23NASDAQ.COM
Significant Wednesday Options Trading: AI, BC, ALEC

  • Brunswick Corp. Options Activity: Brunswick Corp. (BC) has seen a trading volume of 4,284 options contracts today, equating to about 428,400 underlying shares, which is 63.1% of its average daily trading volume over the past month.

  • High Volume Call Option for Brunswick: The $70 strike call option expiring on November 21, 2025, has particularly high activity, with 1,682 contracts traded, representing approximately 168,200 underlying shares.

  • Alector Inc. Options Activity: Alector Inc. (ALEC) has recorded a volume of 7,980 options contracts today, representing around 798,000 underlying shares, or 62.4% of its average daily trading volume over the past month.

  • High Volume Call Option for Alector: The $2.50 strike call option expiring on December 19, 2025, has seen significant trading, with 3,754 contracts exchanged, corresponding to about 375,400 underlying shares.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alector Inc (ALEC) stock price today?

The current price of ALEC is 1.21 USD — it has increased 6.14 % in the last trading day.

arrow icon

What is Alector Inc (ALEC)'s business?

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

arrow icon

What is the price predicton of ALEC Stock?

Wall Street analysts forecast ALEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALEC is 2.06 USD with a low forecast of 0.75 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alector Inc (ALEC)'s revenue for the last quarter?

Alector Inc revenue for the last quarter amounts to 3.26M USD, decreased -78.75 % YoY.

arrow icon

What is Alector Inc (ALEC)'s earnings per share (EPS) for the last quarter?

Alector Inc. EPS for the last quarter amounts to -0.34 USD, decreased -20.93 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alector Inc (ALEC)'s fundamentals?

The market is revising Downward the revenue expectations for Alector, Inc. (ALEC) for FY2025, with the revenue forecasts being adjusted by -4.87% over the past three months. During the same period, the stock price has changed by -59.80%.
arrow icon

How many employees does Alector Inc (ALEC). have?

Alector Inc (ALEC) has 238 emplpoyees as of December 05 2025.

arrow icon

What is Alector Inc (ALEC) market cap?

Today ALEC has the market capitalization of 124.43M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free